Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research interests include Lymphoma Diagnosis and Treatment, CNS Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, and Viral-associated cancers and disorders.
Immunodeficiency-associated primary CNS lymphomas: An International Primary CNS Lymphoma Collaborative Group (IPCG) Study
TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial.
Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline.
The role of PET/CT in peripheral T-cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO-T trial.
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results
The management of newly diagnosed large B‐cell lymphoma: A British Society for Haematology Guideline
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.
The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline.
Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.
Central nervous system prophylaxis in large B-cell lymphoma: A British Society for Haematology Good Practice Paper.
In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T‐Cell Neoplasms
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma
How I treat secondary CNS involvement by aggressive lymphomas
Management of secondary central nervous system lymphoma.
A retrospective study of MYC rearranged diffuse large B-cell lymphoma in the context of the new WHO and ICC classifications.
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
A national service for delivering <scp>CD19 CAR‐T</scp>in large B‐cell lymphoma – The <scp>UK</scp> real‐world experience
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients
UCL Discovery (University College London) 2022cited by 76position: middle
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
Prolonged SARS-CoV-2 shedding in a person living with advanced HIV and diffuse large B-cell lymphoma: a case report
Impact of severe acute respiratory syndrome coronavirus‐2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group
Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis
Low seropositivity and sub-optimal neutralisation rates in patients fully vaccinated against COVID-19 with B cell malignancies
Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report